₹102.87
−1.99%NSE close, 16 Nov 2026
+22.45%
Valiant Laboratories is a small cap company, listed on NSE under the symbol VALIANTLAB. At ₹102.87 a share, the market values the whole company at ₹559 crore.
In FY26, it reported sales of ₹237 crore and a net loss of ₹3 crore, an operating margin of 2.7%.
The market values the company at 34.5 times its profit over the last twelve months and 1.68 times its book value; its return on equity is 4.9% and its borrowings are 0.11 times its equity.
Promoters hold 74.94% of the shares. Foreign institutions hold 0.07%, and domestic institutions, mutual funds among them, 0.08%.
Over the past year the share price has risen 26.8%, and it is 27.2% below its 52-week high.
₹ crore. Consolidated figures.
Sad demise of the member of a Promoter Group of the Company
The financial results for the period ended September 30, 2026.
A copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 28, 2026
Investment in AMPYR Renewable Energy Resources Twelve A Private Limited
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 40.5 | 30.6 | 18.9 | 21.5 | 35.2 | 57.8 | 46.8 | 46.2 | 52.5 | 92.0 | 115 | 117 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 46.8 | 35.1 | 21.3 | 28.2 | 34.6 | 54.0 | 44.4 | 46.1 | 53.4 | 87.2 | 86.0 | 112 |
| Operating profit | −6.3 | −4.5 | −2.4 | −6.7 | 0.6 | 3.8 | 2.4 | 0.1 | −0.9 | 4.8 | 29.3 | 5.2 |
| Operating margin | -15.6% | -14.8% | -12.7% | -31.4% | 1.8% | 6.6% | 5.1% | 0.2% | -1.7% | 5.2% | 25.4% | 4.4% |
| Other income | 1.8 | 2.5 | 2.8 | 3.4 | 1.6 | −2.3 | 0.7 | 0.9 | 0.6 | 0.2 | 0.9 | 0.1 |
| Interest | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 1.0 | 1.1 | 1.0 |
| Depreciation | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 2.1 | 2.9 | 2.9 | 3.7 |
| Profit before tax | −5.0 | −2.6 | −0.2 | −3.9 | 1.6 | 0.9 | 2.5 | 0.3 | −3.0 | 1.1 | 26.2 | 0.7 |
| Tax | −1.5 | −1.3 | 0.4 | 0.8 | −0.7 | 0.2 | 0.6 | 0.1 | 4.1 | −0.7 | 5.1 | 0.3 |
| Net profit | −3.5 | −1.2 | −0.5 | −4.7 | 2.4 | 0.7 | 1.8 | 0.2 | −7.1 | 1.8 | 21.1 | 0.4 |
| EPS (₹) | -0.81 | -0.33 | -0.12 | -1.09 | 0.54 | 0.16 | 0.42 | 0.04 | -1.30 | 0.32 | 3.89 | 0.08 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 1.3 | −10.4 | 18.7 |
| From investing | −52.8 | 7.3 | −11.4 |
| From financing | 44.7 | 1.8 | −7.1 |
| Spent on fixed assets | −114 | −34.2 | −4.8 |
| Free cash flow | −113 | −44.6 | 13.9 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | -1.6% | -1.4% |
| Operating margin | -3.5% | 2.7% |
| Return on equity | -0.9% | -1.1% |
| Return on capital employed | -0.4% | 0.8% |
| Return on assets | -0.6% | -0.7% |
| Debt to equity | 0.52 | 0.14 |
| Interest coverage | -7.40 | 1.40 |
| Debt to assets | 0.30 | 0.10 |
| Current ratio | 3.23 | 1.91 |
| Quick ratio | 3.16 | 1.53 |
| Cash ratio | 0.08 | 0.03 |
| Asset turnover | 0.33 | 0.51 |
| Fixed asset turnover | 2.76 | 1.05 |
| Inventory turnover | 29.20 | 4.30 |
| Receivables turnover | 1.80 | 2.50 |
| Gross margin | 12.6% | 17.0% |
| Effective tax rate | – | 524.7% |
Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015
Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26
Monitoring Agency Report for quarter ended June 30, 2026
Change in Corporate Office of the company.
Change in Registered Office of the company.
Additional investment in Valiant Advanced Sciences Private Limited ("VASPL") up to an amount not exceeding Rs. 60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares
Change in Director(s) of the company.
The financial results for the period ended Jun 30, 2026.
The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the…